Pharming Group N.V. (PHAR) Receivables (2019 - 2024)

Pharming (PHAR) has disclosed Receivables for 6 consecutive years, with $43.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables fell 10.72% year-over-year to $43.1 million, compared with a TTM value of $43.1 million through Dec 2024, down 10.72%, and an annual FY2024 reading of $43.1 million, down 10.72% over the prior year.
  • Receivables was $43.1 million for Q4 2024 at Pharming, down from $48.3 million in the prior quarter.
  • Across five years, Receivables topped out at $48.3 million in Q4 2023 and bottomed at $22.1 million in Q4 2022.
  • Average Receivables over 5 years is $36.6 million, with a median of $37.1 million recorded in 2020.
  • The sharpest move saw Receivables tumbled 31.73% in 2022, then surged 118.75% in 2023.
  • Year by year, Receivables stood at $37.1 million in 2020, then fell by 12.7% to $32.3 million in 2021, then crashed by 31.73% to $22.1 million in 2022, then soared by 118.75% to $48.3 million in 2023, then dropped by 10.72% to $43.1 million in 2024.
  • Business Quant data shows Receivables for PHAR at $43.1 million in Q4 2024, $48.3 million in Q4 2023, and $22.1 million in Q4 2022.